Skip Navigation
Find a Doctor
 
 
 
 

 

Search for
other physicians or researchers.

Find a Doctor
Photo of Dr. Richard Zellars

Richard Ceric Zellars, MD

Associate Professor of Radiation Oncology and Molecular Radiation Sciences
Male
Appointment Phone

410-502-8000

Primary Location

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

View All Locations
Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-0773 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »

Titles

  • Associate Professor of Radiation Oncology and Molecular Radiation Sciences
  • Associate Professor of Oncology

Centers & Institutes

  • Avon Foundation Breast Center
  • Sidney Kimmel Comprehensive Cancer Center

Expertise

Breast Cancer, Cervical Cancer, Endometrial Cancer, Gynecologic Cancers, Radiation Oncology

Research Interests

Breast Cancer

Biography

Associate Professor of Radiation Oncology and Molecular Radiation Sciences
Associate Professor of Oncology
Assistant Director of Clinical Trial Accrual, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

The complexity and prevalence of breast cancer drew Richard Zellars to this area of oncology. The bravery of breast cancer patients for whom, in Zellars’ experience, “much of the regular superficial stuff of life seems to fall to the wayside,” has made him ever more loyal to treating patients with the disease and conducting related research.

“My [research] goals are basically to improve the facility, safety and efficacy of radiation for breast cancer. We want it to be better, safer, and easier,” Dr. Zellars says. With these goals in mind, he describes some of his current research projects as “super exciting”.

The first study, which seeks both to shorten the course of treatment for breast cancer patients while making it more effective, involves treating only part of the breast (a method called partial breast irradiation) while simultaneously treating patients with chemotherapy. Previously, this combined method of treatment had been considered too toxic for patients. But delivering the radiation to a much more targeted location as opposed to the entire breast greatly reduces toxicity. And, Dr. Zellars points out, the combined treatment may improve patients’ outcomes.

In another cutting-edge study, he is examining the effects of combining radiation with PARP inhibitors—a relatively new class of drugs that have been shown in laboratory studies to prevent cancer cells from repairing broken DNA strands. Combining PARP inhibitors with radiation, theorizes Dr. Zellars, should kill more cancer cells than radiation alone.

“We’re offering this to women who have had pre-operative chemotherapy but whose cancer hasn’t gone away completely. Giving this combined treatment before surgery will hopefully minimize surgery required [after chemotherapy] and reduce the risk of the cancer returning,” he explains.

Dr. Zellars credits the support of his colleagues with his ability to conduct such innovative research. “It’s a phenomenal group of forward-thinking, open-minded breast physicians. Because of this team, we are re-thinking the breast cancer question. We’re willing to look at things we once held as fact and ask if they still hold true,” he says.

Dr. Richard C. Zellars is an Assistant Professor in the Department of Radiation Oncology and Molecular Radiation Sciences and in the Department of Oncology. He is a graduate of the Johns Hopkins School of Medicine and completed his residency in Radiation Oncology at the University of Michigan.

Previous appointments include Assistant Professorship in the Department of Radiation Medicine at Georgetown University Medical Center and Vice Chairmanship of the Department of Radiation Oncology at the University of Texas at San Antonio. Dr. Zellars primary clinical and research interests are in the treatment of Breast and Gynecologic cancers. He has received several grants to perform research in the treatment of breast cancer. Presently he is enrolling patients into a partial breast irradiation and concurrent chemotherapy trial of his design. This clinical trial decreases the duration of standard breast cancer therapy (chemotherapy followed by radiation after lumpectomy) from 5-6 months to less than 2 months.

Additional Resources +
  • Education +

    Training

    • Johns Hopkins University School of Medicine ( Baltimore MD ) (1991)

    Residencies

    • University of Michigan Health System/Radiation Oncology ( Ann Arbor MI ) (1996)

    Certifications

    • Radiation Oncology, American Board of Radiology (2006)
  • Research & Publications +

    Selected Publications

    Ford, E.C.; Lavely, W.C.; Frassica, D.A.; Myers, L.T.; Asrari, F.; Wahl, R.L.; Zellars, R.C. Comparison of FDG-PET/CT and CT for delineation of lumpectomy cavity for partial breast irradiation. Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):595-602.

    Balmanoukian, A.; Zhang, Z.; Jeter, S.; Slater, S.; Armstrong, D.K.; Emens, L.A.; Fetting, J.H.; Wolff, A.C.; Davidson, N.E.; Jacobs, L.; Lange, J.; Tsangaris, T.N.; Zellars, R.; Gabrielson, E.; Stearns, V. African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women. J Clin Oncol. 2009 Aug 1;27(22):e35-37; author reply e38-39.

    Ford, E.C.; Gaudette, R.; Myers, L.; Vanderver, B.; Engineer, L.; Zellars, R.; Song, D.Y.; Wong, J.; Deweese, T.L. Evaluation of safety in a radiation oncology setting using failure mode and effects analysis. Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):852-858.

    Zellars, R.C. Deemphasize dogma: consider the local control-overall survival link. Oncology (Williston Park). 2009 Jul;23(8):679-680.

    Zellars, R.C.; Stearns, V.; Frassica, D.; Asrari, F.; Tsangaris, T.; Myers, L.; DiPasquale, S.; Lange, J.R.; Jacobs, L.K.; Emens, L.A.; Armstrong, D.K.; Fetting, J.H.; Garrett-Mayer, E.; Davidson, N.E.; Wolff, A.C. Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. J Clin Oncol. 2009 Jun 10;27(17):2816-2822.
    Chumsri, S.; Jeter, S.; Jacobs, L.K.; Nassar, H.; Armstrong, D.K.; Emens, L.A.; Fetting, J.H.; Lange, J.R.; Riley, C.; Tsangaris, T.N.; Wolff, A.C.; Zellars, R.; Zhang, Z.; Stearns, V. Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer. Clin Breast Cancer. 2010 Feb;10(1):40-45.


    Ford, E.C., Lavely, W.C., Frassica, D.A., Myers, L.T., Asrari, F., Wahl, R.L., and Zellars, R.C. (2008). Comparison of FDG-PET/CT and CT for delineation of lumpectomy cavity for partial breast irradiation. Int J Radiat Oncol Biol Phys 71, 595-602.

    Zellars, R.C., Stearns, V., Frassica, D., Asrari, F., Tsangaris, T., Myers, L., DiPasquale, S., Lange, J., Jacobs, L., Emens, L.A., Armstrong, D., Fetting, J., Garrett-Mayer, E., Davidson, N.E. and Wolff, A.C. (2009). Feasibility Trial of Partial Breast Irradiation with Concurrent Dose-Dense Doxorubicin and Cyclophosphamide in Early Stage Breast Cancer. J Clin Onc 27, 2816-2822.

  • Academic Affiliations & Courses +
  • Activities & Honors +
  • Videos & Media +

    Videos

    Johns Hopkins Radiation Oncology at Green Spring Station

  • Upcoming Events +
  • Contact & Locations +

    Locations

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    401 N. Broadway
    Baltimore, MD 21231
    Phone: 410-502-1421
    Appointment Phone: 410-502-8000
    Fax: 410-502-1419
    Location Map
    Johns Hopkins Medicine - Green Spring Station
    10753 Falls Road
    Pavilion II
    Baltimore, MD 21093
    Phone: 410-502-8001
    Appointment Phone: 410-502-8001
    Location Map

    Department/Division

    • Radiation Oncology and Molecular Radiation Sciences

Is This You? Edit Profile

 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer